金吾财讯 | 阿斯利康(AZN)盘前股价走高，暂升1.52%，报77.26美元。消息面上，在近期于美国加州圣地亚哥举办的美国过敏、哮喘和免疫学会年会（AAAAI）上，阿斯利康一款用于重度哮喘治疗的药物特泽利尤单抗（Tezepelumab），在慢性鼻窦炎伴鼻息肉的治疗领域呈现出令人瞩目的积极效果。依据一项三期临床研究成果，特泽利尤单抗能够显著缓解慢性鼻窦炎伴鼻息肉患者的鼻塞症状，有效缩小息肉体积，近乎让患者无需进行手术治疗。这一最新研究数据已发表于《新英格兰医学杂志》，并以最新突破性研究口头报告的形式，在 2025 年 AAAAI 大会上予以发布。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.